Covid-19 and weak data force pipeline revamp at Reata, but the best trials go forward — with some creative adaptions
A confluence of weak clinical results and the rising tide of problems besetting clinical trials in the age of coronavirus has scuttled a significant part of the pipeline effort at Reata Pharmaceuticals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.